CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 143 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $0 | – | 102 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 102 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | – | 102 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | -100.0% | 102 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 102 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 102 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 102 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | -50.0% | 102 | -64.2% | 0.00% | – |
| Q3 2020 | $2,000 | 0.0% | 285 | 0.0% | 0.00% | – |
| Q2 2020 | $2,000 | 0.0% | 285 | 0.0% | 0.00% | – |
| Q1 2020 | $2,000 | 0.0% | 285 | 0.0% | 0.00% | – |
| Q4 2019 | $2,000 | 0.0% | 285 | 0.0% | 0.00% | – |
| Q3 2019 | $2,000 | -33.3% | 285 | 0.0% | 0.00% | – |
| Q2 2019 | $3,000 | +50.0% | 285 | +34.4% | 0.00% | – |
| Q1 2019 | $2,000 | -33.3% | 212 | 0.0% | 0.00% | – |
| Q4 2018 | $3,000 | -25.0% | 212 | 0.0% | 0.00% | – |
| Q3 2018 | $4,000 | -20.0% | 212 | 0.0% | 0.00% | – |
| Q2 2018 | $5,000 | -16.7% | 212 | 0.0% | 0.00% | – |
| Q1 2018 | $6,000 | – | 212 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 476,110 | $3,956,000 | 2.65% |
| MPM BioImpact LLC | 855,437 | $7,109,000 | 2.52% |
| Exane Asset Management | 87,876 | $730,250,000 | 0.90% |
| Congress Park Capital LLC | 94,661 | $787,000 | 0.58% |
| Perceptive Advisors | 3,253,923 | $27,040,000 | 0.54% |
| BVF INC/IL | 766,148 | $6,367,000 | 0.48% |
| RTW INVESTMENTS, LP | 1,039,593 | $8,639,000 | 0.33% |
| EcoR1 Capital, LLC | 410,000 | $3,407,000 | 0.31% |
| DAFNA Capital Management LLC | 100,000 | $831,000 | 0.28% |
| HARBOURVEST PARTNERS LLC | 79,193 | $658,000 | 0.27% |